Oxycomplex NS

Oxycomplex NS For the control and treatment of infectious
diseases of cattle caused by or associated with
organisms sensitive to oxytetracycline, where
concurrent analgesic, anti-inflammatory,
antiendotoxic or antipyretic therapy is desired.
The product is especially indicated for the
treatment of respiratory disease (particularly that
associated with Pasteurella infection) and acute
mastitis.
CONTRAINDICATIONS
Do not administer other NSAIDs concurrently or
within 24 hours of each other.
Use is contra-indicated in animals suffering from
cardiac, hepatic or renal disease, where there is
the possibility of gastro-intestinal ulceration or
bleeding, where there is evidence of a blood
dyscrasia or hypersensitivity to the product.
Not suitable for donkeys or horses.
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Some NSAIDs may be highly bound to plasma
proteins and compete with other highly bound
drugs to produce an increase in non-bound
pharmacologically active concentrations, which
can lead to toxic effects.
Oxycomplex NS ,Use in any animal less than 6 weeks of age or in
aged animals may involve additional risk.
If such use cannot be avoided animals may require
a reduced dosage and careful clinical
management.
Avoid use in any dehydrated, hypovolaemic or
hypotensive animal as there is a potential risk of
renal toxicity. It is preferable that flunixin is not
administered to animals undergoing general
anaesthesia until fully recovered.
Concurrent administration of methoxyflurane
anaesthesia or other potentially nephroto

SPECIAL PRECAUTIONS FOR USE
Use of the product should be based on
susceptibility testing of the bacteria isolated from
the animal. If this is not possible therapy should
be based on local (regional, farm level)
epidemiological information about susceptibility
of the target bacteria.
ADVERSE REACTIONS
Prolonged use of NSAIDs, including flunixin, may
predispose or lead to gastrointestinal ulceration.
USE DURING PREGNANCY, LACTATION OR LAY
Safe for use in pregnant and lactating animals.
The use of tetracyclines during the period of tooth
development, including late pregnancy, may lead
to tooth discolouration.
INTERACTION WITH OTHER MEDICINAL
PRODUCTS AND OTHER FORMS OF
INTERACTIONS
The product may potentiate the effects of
Warfarin and related drugs. Because of their
common mode of action, flunixin may potentiate
and be potentiated by other NSAIDs which act by
interfering with prostaglandin synthesis.
Where other products are to administered
concurrently, drug capability should be carefully
monitored.
Corticosteroids should bot be used concurrently
with this product.
AMOUNTS TO BE ADMINISTERED AND
ADMINISTRATION ROUTE
By intravenous or deep intramuscular injection at
a rate of 1 ml per 10 kg bodyweight (equivalent to
10 mg oxytetracycline and 2 mg flunixin per kg
bodyweight) daily for up to 5 days.
Do not inject more than 20 ml intramuscularly at
a single site. Where the dose exceeds 20 ml it
should be divided between two or more sites, as
appropriate.
OVERDOSE
Overdosing by intramuscular injection may give
rise to swellings at the site of injection. Treatment
should be symptomatic.
WITHDRAWAL PERIODS
Meat: Animals must not be slaughtered for human
consumption during treatment. Cattle may be
slaughtered for human consumption only after 28
days following the last treatment.
Milk: Milk for human consumption must not be
takenhttps://camelhorsemedrace.com/https://camelhorsemedrace.com/